Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 2/20 | 0.62 |
| ▸ | CASP6 | P55212 | 1/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.50 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.46 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.46 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.46 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.46 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.46 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.46 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7277302 | 0.84 | QDPR (0.69) | QDPRPRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL12874043 | 0.84 | QDPR (0.64) | QDPRSLC18A3NPY5RALDH1A1MCHR1 | |
| SCHEMBL265000 | 0.84 | SLC18A3 (0.51) | QDPRSLC18A3ALDH1A1POLBKCNH2 | |
| SCHEMBL11977020 | 0.83 | QDPR (0.59) | QDPRPRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL608705 | 0.83 | QDPR (0.55) | QDPRCASP6GFERDGAT1PRKAB2 | |
| SCHEMBL15300836 | 0.83 | QDPR (0.62) | QDPRDGAT1KDM1AMAOAMAOB | |
| SCHEMBL7287663 | 0.83 | QDPR (0.62) | QDPRPRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL19658652 | 0.83 | QDPR (0.62) | QDPRALDH1A1MCHR1KCNH2CCR1 | |
| SCHEMBL10460507 | 0.83 | QDPR (0.62) | QDPRNPY5RMCHR1KCNH2CCR1 | |
| SCHEMBL1473424 | 0.82 | QDPR (0.61) | QDPRSLC18A3NPY5RKDM4EBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3752497-B1 | P300/CBP HAT INHIBITORS | CONSTELLATION PHARMACEUTICALS INC (US) | 2024-07-17 | — | — | EP | disclosed |
| EP-3752497-B1 | P300/CBP HAT INHIBITORS | CONSTELLATION PHARMACEUTICALS INC (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-112218857-B | P300/CBP HAT inhibitors and methods of use thereof | 星座制药公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-114450005-A | Compounds for the treatment of neurological disorders | 星座制药公司 | 2022-05-06 | — | — | CN | disclosed |
| US-20210115008-A1 | P300/CBP HAT INHIBITORS | CONSTELLATION PHARMACEUTICALS, INC. | 2021-04-22 | — | — | US | disclosed |
| WO-2021021893-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| CN-112218857-A | P300/CBP HAT inhibitors and methods of use thereof | 星座制药公司 | 2021-01-12 | — | — | CN | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| WO-2019161162-A1 | P300/CBP HAT INHIBITORS | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2019-08-22 | — | — | WO | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-20080051402-A1 | METHOD OF INHIBITING C-KIT KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2008-02-28 | — | — | US | disclosed |
| WO-2007140222-A2 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007140222-A2 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2007-12-06 | — | — | WO | disclosed |
| US-20070149572-A1 | METHOD OF INHIBITING FLT3 KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-28 | — | — | US | disclosed |
| US-20070149572-A1 | METHOD OF INHIBITING FLT3 KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-28 | — | — | US | disclosed |
| US-20070149572-A1 | METHOD OF INHIBITING FLT3 KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-28 | — | — | US | disclosed |
| WO-2007048088-A2 | METHOD OF INHIBITING FLT3 KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-26 | — | — | WO | disclosed |
| US-20060281788-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-14 | — | — | US | disclosed |
| US-20060189623-A1 | Inhibitors of c-fms kinase | ILLIG CARL R | 2006-08-24 | — | — | US | disclosed |
| US-20060148812-A1 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189623-A1 | Inhibitors of c-fms kinase | MUSK, TYK2, FES | QDPR 4792/4885CASP6 1708/4885GFER 3790/4885 |
| US-20210115008-A1 | P300/CBP HAT INHIBITORS | EP300, HDAC1, KAT2A | QDPR 4702/4885CASP6 4095/4885GFER 4697/4885 |
| US-20060281788-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR | FLT3, MCL1, CSF1R | QDPR 2782/4885CASP6 1847/4885GFER 4440/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | QDPR 3390/4885CASP6 3379/4885GFER 3828/4885 |
| US-20060148812-A1 | Inhibitors of c-fms kinase | MUSK, TYK2, FES | QDPR 4792/4885CASP6 1708/4885GFER 3790/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | QDPR 3201/4885CASP6 3264/4885GFER 3792/4885 |
| US-20080051402-A1 | METHOD OF INHIBITING C-KIT KINASE | KIT, CHUK, MAP3K13 | QDPR 1086/4885CASP6 1054/4885GFER 3951/4885 |
| US-20070149572-A1 | METHOD OF INHIBITING FLT3 KINASE | FLT3, PLK1, PHKG1 | QDPR 2795/4885CASP6 1003/4885GFER 3843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.